Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
Advertisement
Merck announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.
Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition, Weinreich has founded multiple companies and served as a venture capitalist, board member, and biotech CEO. Weinreich joins Merck from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor. His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Executive Medical Director, Global Product Area Leader (Angiogenesis) at Amgen.
“Scientific innovation is the engine that drives everything we do to transform patient care,” said Danny Bar Zohar, MD, Member of the Executive Board of Merck, and CEO Healthcare. “In David, we have a leader with a unique combination of deep scientific expertise, immense experience in drug development and successfully bringing drugs to the finish line, and global perspective—along with the clarity and boldness to shape a next-generation R&D strategy. His appointment marks an exciting step forward as we work to bring more medicines to more patients, faster.”
As Global Head of R&D and Chief Medical Officer, Weinreich will lead Research and Development for the Healthcare business sector of Merck, including Medical Affairs. Weinreich brings to Merck an exceptional record of success in leading early-stage and late-stage development, with leadership responsibility in achieving approvals across the globe for multiple therapies and indications. He has extensive experience in shaping R&D strategies that deliver meaningful value to patients and drive sustainable growth for future innovation investments. He also has effectively managed large and complex pipelines and global R&D teams.
“Joining Merck at such a pivotal moment in its growth journey offers a rare opportunity to lead scientific innovation with the potential to have a profound impact on patients’ lives,” said Dr. Weinreich. “This is an organization with a strong legacy, deep scientific capabilities, and a clear commitment to delivering meaningful value where it’s needed most. I look forward to working with teams around the world to advance a clear R&D strategy grounded in urgency, collaboration, and purpose.”
Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics
Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”
Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026
Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management
Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany
Herz- und Diabeteszentrum Nordrhein-Westfalen (Universitätsklinik der Ruhr-Universität Bochum) - Bad Oeynhausen, Germany
Lead Discovery Center GmbH - Dortmund, Germany
Living heart muscle slices drive RNA research into heart failure - Researchers place living human heart tissue in a nutrient solution and use it to test new drugs and innovative approaches to combat heart failure
Empa - St. Gallen, Switzerland
What Do Spiders Have in Common with Batteries? - Spider silk inspires new class of functional synthetic polymers: Conducting protein-based material could be used in fuel cells, batteries or act as sensor
Sensors against superbugs - Dangerous increase in antimicrobial resistance: Detect resistant pathogens faster and start customized treatment in good time
